Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 434

1.

Ankylosing Spondylitis Response to TNF Inhibition Is Gender Specific: A 6-Year Cohort Study

Murray C, Fearon C, Dockery M, Moran D, Heffernan E, Fitzgerald O, Veale DJ, Harty L.

Ir Med J. 2018 Oct 11;111(9):820.

PMID:
30556668
2.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Callis Duffin K, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2018 Dec 15. pii: jrheum.181077. doi: 10.3899/jrheum.181077. [Epub ahead of print]

PMID:
30554154
3.

Inflammatory back pain criteria perform well in subset of patients with active axial psoriatic arthritis but not among patients with established axial disease.

Haroon M, Gallagher P, FitzGerald O.

Ann Rheum Dis. 2018 Dec 14. pii: annrheumdis-2018-214583. doi: 10.1136/annrheumdis-2018-214583. [Epub ahead of print] No abstract available.

PMID:
30552175
4.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

5.

Advancing research paradigms and pathophysiological pathways in psoriatic arthritis and ankylosing spondylitis: Proceedings of the 2017 Platform for the Exchange of Expertise and Research (PEER) meeting.

Abraham S, Barton A, Eder L, Lim A, McGonagle D, McHugh N, Pennington S, Sengupta R, Siebert S, Bowness P, Schafer PH, Cullen E, FitzGerald O.

Semin Arthritis Rheum. 2018 Oct 15. pii: S0049-0172(18)30417-7. doi: 10.1016/j.semarthrit.2018.10.008. [Epub ahead of print] No abstract available.

6.

Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set.

Elmamoun M, Leung YY, O'Sullivan D, Steinkoenig I, Chandran V, Gladman DD, FitzGerald OM, Orbai AM, Eder L.

J Rheumatol. 2018 Nov 1. pii: jrheum.180195. doi: 10.3899/jrheum.180195. [Epub ahead of print]

PMID:
30385708
7.

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.

Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E.

Arthritis Res Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0.

8.

Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry.

Füssl F, Trappe A, Cook K, Scheffler K, Fitzgerald O, Bones J.

MAbs. 2019 Jan;11(1):116-128. doi: 10.1080/19420862.2018.1531664. Epub 2018 Nov 11.

9.

Modifications of Cardiovascular Risk Scores, But Not Standard Risk Scores, Improve Identification of Asymptomatic Coronary Artery Disease in Psoriatic Arthritis.

Haroon M, Szentpetery A, Dodd JD, Fitzgerald O.

J Rheumatol. 2018 Aug;45(9):1329-1330. doi: 10.3899/jrheum.180299. No abstract available.

PMID:
30173181
10.

Vascular measures of atherosclerosis in detrusor overactivity and controls.

Ladanchuk T, Kwak S, Bates L, Parkin K, Harris K, Fitzgerald O, Lynch W, Moore KH.

Neurourol Urodyn. 2018 Nov;37(8):2827-2832. doi: 10.1002/nau.23784. Epub 2018 Aug 14.

PMID:
30106191
11.

Combined inhibition of tumour necrosis factor-alpha and interleukin-12/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?

De Marco G, McGonagle D, Mathieson HR, Merashli M, Magee C, FitzGerald O, Goodfield M, Marzo-Ortega H.

Rheumatology (Oxford). 2018 Nov 1;57(11):2053-2055. doi: 10.1093/rheumatology/key199. No abstract available.

PMID:
29982709
12.

Advanced musculoskeletal physiotherapy practice in Ireland: A National Survey.

Fennelly O, Blake C, FitzGerald O, Breen R, O'Sullivan C, O'Mir M, Desmeules F, Cunningham C.

Musculoskeletal Care. 2018 Dec;16(4):425-432. doi: 10.1002/msc.1351. Epub 2018 Jun 21.

PMID:
29927063
13.

Advanced practice physiotherapy-led triage in Irish orthopaedic and rheumatology services: national data audit.

Fennelly O, Blake C, FitzGerald O, Breen R, Ashton J, Brennan A, Caffrey A, Desmeules F, Cunningham C.

BMC Musculoskelet Disord. 2018 Jun 1;19(1):181. doi: 10.1186/s12891-018-2106-7.

14.

Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:54-61. doi: 10.3899/jrheum.180141.

PMID:
29858357
15.

GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2018 Jun;94:48-51. doi: 10.3899/jrheum.180139.

PMID:
29858355
16.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
17.

Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines.

Murray KE, Moore L, O'Brien C, Clohessy A, Brophy C, Minnock P, FitzGerald O, Molloy ES, Mongey AB, Higgins S, Higgins MF, Mc Auliffe FM, Veale DJ.

Ir J Med Sci. 2019 Feb;188(1):169-172. doi: 10.1007/s11845-018-1829-7. Epub 2018 May 10.

PMID:
29748892
18.
19.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, Hoepken B, Bauer L, Irvin-Sellers O, Khraishi M, Peterson L, Turkiewicz A, Wollenhaupt J, Mease PJ.

RMD Open. 2018 Mar 14;4(1):e000582. doi: 10.1136/rmdopen-2017-000582. eCollection 2018. Erratum in: RMD Open. 2018 Mar 26;4(1):.

20.

Work Outcomes in Patients Who Stay at Work Despite Musculoskeletal Pain.

Cochrane A, Higgins NM, Rothwell C, Ashton J, Breen R, Corcoran O, FitzGerald O, Gallagher P, Desmond D.

J Occup Rehabil. 2018 Sep;28(3):559-567. doi: 10.1007/s10926-017-9748-4.

PMID:
29236203
21.

Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity.

Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, Fleming H, Duignan J, Dodd JD, FitzGerald O.

Arthritis Rheumatol. 2018 Mar;70(3):396-407. doi: 10.1002/art.40389. Epub 2018 Feb 6.

PMID:
29193860
22.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

23.

Remission in psoriatic arthritis-where are we now?

Coates LC, Conaghan PG, D'Agostino MA, De Wit M, FitzGerald O, Kvien TK, Lories R, Mease P, Nash P, Schett G, Soriano ER, Emery P.

Rheumatology (Oxford). 2018 Aug 1;57(8):1321-1331. doi: 10.1093/rheumatology/kex344.

24.

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS.

N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975.

25.

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.

Højgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R.

Semin Arthritis Rheum. 2018 Apr;47(5):654-665. doi: 10.1016/j.semarthrit.2017.09.002. Epub 2017 Sep 9. Review.

26.

Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis.

Bowes J, Ashcroft J, Dand N, Jalali-Najafabadi F, Bellou E, Ho P, Marzo-Ortega H, Helliwell PS, Feletar M, Ryan AW, Kane DJ, Korendowych E, Simpson MA, Packham J, McManus R, Brown MA, Smith CH, Barker JN, McHugh N, FitzGerald O, Warren RB, Barton A.

Ann Rheum Dis. 2017 Oct;76(10):1774-1779. doi: 10.1136/annrheumdis-2017-211414. Epub 2017 Aug 18.

27.

A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis.

Tillett W, Dures E, Hewlett S, Helliwell PS, FitzGerald O, Brooke M, James J, Lord J, Bowen C, de Wit M, Orbai AM, McHugh N; PROMPT study group.

J Rheumatol. 2017 Oct;44(10):1445-1452. doi: 10.3899/jrheum.161459. Epub 2017 Aug 1.

PMID:
28765241
28.

Assisted reproductive technology in Australia and New Zealand: cumulative live birth rates as measures of success.

Chambers GM, Paul RC, Harris K, Fitzgerald O, Boothroyd CV, Rombauts L, Chapman MG, Jorm L.

Med J Aust. 2017 Aug 7;207(3):114-118.

PMID:
28764619
29.

Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

McArdle A, Pennington S, FitzGerald O.

Clin Rev Allergy Immunol. 2018 Dec;55(3):271-294. doi: 10.1007/s12016-017-8630-7. Review.

PMID:
28748366
30.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

31.

Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.

Szentpetery A, Heffernan E, Gogarty M, Mellerick L, McCormack J, Haroon M, Elmamoun M, Gallagher P, Kelly G, Fabre A, Kirby B, FitzGerald O.

Arthritis Res Ther. 2017 Jul 5;19(1):158. doi: 10.1186/s13075-017-1364-3.

32.

The Effect of Anterior Uveitis and Previously Undiagnosed Spondyloarthritis: Results from the DUET Cohort.

O'Rourke M, Haroon M, Alfarasy S, Ramasamy P, FitzGerald O, Murphy CC.

J Rheumatol. 2017 Sep;44(9):1347-1354. doi: 10.3899/jrheum.170115. Epub 2017 Jul 1.

PMID:
28668811
33.

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.

Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD.

Ann Rheum Dis. 2017 Sep;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4.

34.

GRAPPA 2016 Project Report.

Helliwell PS, FitzGerald O, Coates LC, Callis Duffin K, Mease PJ.

J Rheumatol. 2017 May;44(5):706-710. doi: 10.3899/jrheum.170153.

PMID:
28461534
35.

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O'Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM.

J Rheumatol. 2017 May;44(5):697-700. doi: 10.3899/jrheum.170150.

36.

Proceedings of the GRAPPA 2016 Retreat.

Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS.

J Rheumatol. 2017 May;44(5):668-673. doi: 10.3899/jrheum.170141.

PMID:
28461522
37.

A new era for collaboration?

Packham JC, Abraham S, Kirkham B, Helliwell P, Siebert S, Korendowych E, Fitzgerald O, Parkinson A, Brookes M, Coates L, McHugh N.

Rheumatology (Oxford). 2018 May 1;57(5):775-776. doi: 10.1093/rheumatology/kex083. No abstract available.

PMID:
28407115
38.

Early interventions to promote work participation in people with regional musculoskeletal pain: a systematic review and meta-analysis.

Cochrane A, Higgins NM, FitzGerald O, Gallagher P, Ashton J, Corcoran O, Desmond D.

Clin Rehabil. 2017 Nov;31(11):1466-1481. doi: 10.1177/0269215517699976. Epub 2017 Mar 27.

PMID:
28343440
39.

Effects of targeted therapies on the bone in arthritides.

Szentpétery Á, Horváth Á, Gulyás K, Pethö Z, Bhattoa HP, Szántó S, Szücs G, FitzGerald O, Schett G, Szekanecz Z.

Autoimmun Rev. 2017 Mar;16(3):313-320. doi: 10.1016/j.autrev.2017.01.014. Epub 2017 Jan 31. Review.

PMID:
28159704
40.

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A.

J Rheumatol. 2017 Oct;44(10):1522-1528. doi: 10.3899/jrheum.160904. Epub 2017 Feb 1. Erratum in: J Rheumatol. 2017 Apr;44(4):543.

41.

Fatigue as a symptom in psoriasis and psoriatic arthritis: an observational study.

Tobin AM, Sadlier M, Collins P, Rogers S, FitzGerald O, Kirby B.

Br J Dermatol. 2017 Mar;176(3):827-828. doi: 10.1111/bjd.15258. Epub 2017 Feb 27. No abstract available.

PMID:
28005279
42.

Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis.

Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):270-276. Epub 2016 Dec 13.

43.

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A.

Ann Rheum Dis. 2017 Apr;76(4):673-680. doi: 10.1136/annrheumdis-2016-210242. Epub 2016 Sep 9.

44.

Implications of the diversity of class I HLA associations in psoriatic arthritis.

Winchester R, Giles J, Jadon D, Haroon M, McHugh N, FitzGerald O.

Clin Immunol. 2016 Nov;172:29-33. doi: 10.1016/j.clim.2016.07.019. Epub 2016 Jul 25.

45.

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?

Coates LC, FitzGerald O, Helliwell PS, Paul C.

Semin Arthritis Rheum. 2016 Dec;46(3):291-304. doi: 10.1016/j.semarthrit.2016.05.012. Epub 2016 Jun 2. Review.

46.

Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?

FitzGerald O.

Nat Rev Rheumatol. 2016 May 24;12(6):318-9. doi: 10.1038/nrrheum.2016.84. No abstract available.

PMID:
27215204
47.

GRAPPA 2015 Research and Education Project Reports.

Mease PJ, Helliwell PS, Boehncke WH, Coates LC, FitzGerald O, Gladman DD, Deodhar AA, Callis Duffin K.

J Rheumatol. 2016 May;43(5):979-85. doi: 10.3899/jrheum.160119.

PMID:
27134274
48.

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting.

Orbai AM, Mease PJ, de Wit M, Kalyoncu U, Campbell W, Tillett W, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, Gossec L, Lindsay CA, Steinkoenig I, Helliwell PS, McHugh NJ, Strand V, Ogdie A.

J Rheumatol. 2016 May;43(5):965-9. doi: 10.3899/jrheum.160116.

49.

Replication of a distinct psoriatic arthritis risk variant at the IL23R locus.

Budu-Aggrey A, Bowes J, Loehr S, Uebe S, Zervou MI, Helliwell P, Ryan AW, Kane D, Korendowych E, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Behrens F, Burkhardt H, Huffmeier U, Ho P, Martin J, Castañeda S, Goulielmos G, Reis A, Barton A.

Ann Rheum Dis. 2016 Jul;75(7):1417-8. doi: 10.1136/annrheumdis-2016-209290. Epub 2016 Mar 25. Review. No abstract available.

50.

Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy.

Minnock P, Ringnér A, Bresnihan B, Veale D, FitzGerald O, McKee G.

Musculoskeletal Care. 2017 Mar;15(1):23-35. doi: 10.1002/msc.1136. Epub 2016 Feb 12.

PMID:
26871999

Supplemental Content

Loading ...
Support Center